DEA No. 2820

DEA No. 2820 Brand names, DEA No. 2820 Analogs

DEA No. 2820 Brand Names Mixture

No information avaliable

DEA No. 2820 Chemical_Formula

C₂₀H₂₃NS

DEA No. 2820 RX_link

No information avaliable

DEA No. 2820 fda sheet

DEA No. 2820 msds (material safety sheet)

DEA No. 2820 Synthesis Reference

No information avaliable

DEA No. 2820 Molecular Weight

309.469 g/mol

DEA No. 2820 Melting Point

< 25 ^oC

DEA No. 2820 H₂O Solubility

Soluble as HCl salt

DEA No. 2820 State

Liquid

DEA No. 2820 LogP

5.7

DEA No. 2820 Dosage Forms

Tablets (oral, 1 mg)

DEA No. 2820 Indication

Used for the symptomatic treatment of parkinsonism.

DEA No. 2820 Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

DEA No. 2820 Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

DEA No. 2820 side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

DEA No. 2820 Patient Information

DEA No. 2820 Organisms Affected

Humans and other mammals